{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:35:21Z","timestamp":1790728521588,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anti-inflammatory cytokine IL-35 is produced by regulatory T (Treg) cells to suppress autoimmune and inflammatory responses. The role of IL-35 in type 1 diabetes (T1D) remains to be answered. To elucidate this, we investigated the kinetics of Treg cell response in the multiple low dose streptozotocin induced (MLDSTZ) T1D model and measured the levels of IL-35 in human T1D patients. We found that Treg cells were increased in MLDSTZ mice. However, the Treg cells showed a decreased production of anti-inflammatory (IL-10, IL-35, TGF-\u03b2) and increased pro-inflammatory (IFN-\u03b3, IL-2, IL-17) cytokines, indicating a phenotypic shift of Treg cells under T1D condition. IL-35 administration effectively both prevented development of and counteracted established MLDSTZ T1D, seemingly by induction of Eos expression and IL-35 production in Treg cells, thus reversing the phenotypic shift of the Treg cells. IL-35 administration reversed established hyperglycemia in NOD mouse model of T1D. Moreover, circulating IL-35 levels were decreased in human T1D patients compared to healthy controls. These findings suggest that insufficient IL-35 levels play a pivotal role in the development of T1D and that treatment with IL-35 should be investigated in treatment of T1D and other autoimmune diseases.<\/jats:p>","DOI":"10.1038\/srep12633","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T09:16:35Z","timestamp":1438247795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Interleukin-35 administration counteracts established murine type 1 diabetes \u2013 possible involvement of regulatory T cells"],"prefix":"10.1038","volume":"5","author":[{"given":"Kailash","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Kadesj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lindroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Espes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Ola","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellan","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Thorvaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"BFsrep12633_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","volume":"383","author":"MA Atkinson","year":"2014","unstructured":"Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69\u201382 (2014).","journal-title":"Lancet"},{"key":"BFsrep12633_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nm.3042","volume":"19","author":"J Diana","year":"2013","unstructured":"Diana, J. et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19, 65\u201373 (2013).","journal-title":"Nat Med"},{"key":"BFsrep12633_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20111187","volume":"209","author":"KT Coppieters","year":"2012","unstructured":"Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209, 51\u201360 (2012).","journal-title":"J Exp Med"},{"key":"BFsrep12633_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1084\/jem.20040165","volume":"200","author":"MR Ehrenstein","year":"2004","unstructured":"Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200, 277\u2013285 (2004).","journal-title":"J Exp Med"},{"key":"BFsrep12633_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.coi.2005.09.002","volume":"17","author":"JA Bluestone","year":"2005","unstructured":"Bluestone, J. A. & Tang, Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opi Immunol 17, 638\u2013642 (2005).","journal-title":"Curr Opi Immunol"},{"key":"BFsrep12633_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2337\/diabetes.54.1.92","volume":"54","author":"S Lindley","year":"2005","unstructured":"Lindley, S. et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54, 92\u201399 (2005).","journal-title":"Diabetes"},{"key":"BFsrep12633_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1084\/jem.20031579","volume":"199","author":"V Viglietta","year":"2004","unstructured":"Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199, 971\u2013979 (2004).","journal-title":"J Exp Med"},{"key":"BFsrep12633_CR8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155, 1151\u20131164 (1995).","journal-title":"J Immunol"},{"key":"BFsrep12633_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/83713","volume":"27","author":"CL Bennett","year":"2001","unstructured":"Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27, 20\u201321 (2001).","journal-title":"Nat Genet"},{"key":"BFsrep12633_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/83707","volume":"27","author":"RS Wildin","year":"2001","unstructured":"Wildin, R. S. et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27, 18\u201320 (2001).","journal-title":"Nat Genet"},{"key":"BFsrep12633_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057\u20131061 (2003).","journal-title":"Science"},{"key":"BFsrep12633_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330\u2013336 (2003).","journal-title":"Nat Immunol"},{"key":"BFsrep12633_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ni909","volume":"4","author":"R Khattri","year":"2003","unstructured":"Khattri, R., Cox, T., Yasayko, S. A. & Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4, 337\u2013342 (2003).","journal-title":"Nat Immunol"},{"key":"BFsrep12633_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Ann Rev Immunol 30, 531\u2013564 (2012).","journal-title":"Ann Rev Immunol"},{"key":"BFsrep12633_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali, D. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nat Rev Immunol 8, 523\u2013532 (2008).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep12633_CR16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10, 1000\u20131007 (2009).","journal-title":"Nat Immunol"},{"key":"BFsrep12633_CR17","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1182\/blood-2008-12-195354","volume":"113","author":"MD Sharma","year":"2009","unstructured":"Sharma, M. D. et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113, 6102\u20136111 (2009).","journal-title":"Blood"},{"key":"BFsrep12633_CR18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/eji.200839196","volume":"39","author":"JH Duarte","year":"2009","unstructured":"Duarte, J. H., Zelenay, S., Bergman, M. L., Martins, A. C. & Demengeot, J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Euro J Immunol 39, 948\u2013955 (2009).","journal-title":"Euro J Immunol"},{"key":"BFsrep12633_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni1437","volume":"8","author":"LM Williams","year":"2007","unstructured":"Williams, L. M. & Rudensky, A. Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8, 277\u2013284 (2007).","journal-title":"Nat Immunol"},{"key":"BFsrep12633_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","volume":"28","author":"Q Tang","year":"2008","unstructured":"Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687\u2013697 (2008).","journal-title":"Immunity"},{"key":"BFsrep12633_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.immuni.2009.10.001","volume":"31","author":"G Oldenhove","year":"2009","unstructured":"Oldenhove, G. et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31, 772\u2013786 (2009).","journal-title":"Immunity"},{"key":"BFsrep12633_CR22","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.4049\/jimmunol.0903961","volume":"185","author":"B Vokaer","year":"2010","unstructured":"Vokaer, B. et al. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 185, 3417\u20133425 (2010).","journal-title":"J Immunol"},{"key":"BFsrep12633_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm.3432","volume":"20","author":"N Komatsu","year":"2014","unstructured":"Komatsu, N. et al. Pathogenic conversion of Foxp3(+) T cells into TH17 cells in autoimmune arthritis. Nat Med 20, 62\u201368 (2014).","journal-title":"Nat Med"},{"key":"BFsrep12633_CR24","first-page":"2013","volume":"10","author":"T Wang","year":"2014","unstructured":"Wang, T. et al. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. Ann Rheu Diseases 10, 2013\u2013204228 (2014).","journal-title":"Ann Rheu Diseases"},{"key":"BFsrep12633_CR25","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.4049\/jimmunol.1001860","volume":"185","author":"AK Marwaha","year":"2010","unstructured":"Marwaha, A. K. et al. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 185, 3814\u20133818 (2010).","journal-title":"J Immunol"},{"key":"BFsrep12633_CR26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1126\/science.1176077","volume":"325","author":"F Pan","year":"2009","unstructured":"Pan, F. et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 325, 1142\u20131146 (2009).","journal-title":"Science"},{"key":"BFsrep12633_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.180605","volume":"193","author":"AA Like","year":"1976","unstructured":"Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415\u2013417 (1976).","journal-title":"Science"},{"key":"BFsrep12633_CR28","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","volume":"13","author":"Y Kiniwa","year":"2007","unstructured":"Kiniwa, Y. et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Cli Canc Res 13, 6947\u20136958 (2007).","journal-title":"Cli Canc Res"},{"key":"BFsrep12633_CR29","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.4049\/jimmunol.0904028","volume":"184","author":"AM Thornton","year":"2010","unstructured":"Thornton, A. M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184, 3433\u20133441 (2010).","journal-title":"J Immunol"},{"key":"BFsrep12633_CR30","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20120914","volume":"209","author":"JM Weiss","year":"2012","unstructured":"Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 209, 1723\u20131742, S1721 (2012).","journal-title":"J Exp Med"},{"key":"BFsrep12633_CR31","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1084\/jem.20120822","volume":"209","author":"M Yadav","year":"2012","unstructured":"Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 209, 1713\u20131722, S1711-1719 (2012).","journal-title":"J Exp Med"},{"key":"BFsrep12633_CR32","doi-asserted-by":"publisher","first-page":"7767","DOI":"10.1038\/srep07767","volume":"5","author":"K Singh","year":"2015","unstructured":"Singh, K., Hjort, M., Thorvaldson, L. & Sandler, S. Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice. Sci Rep 5, 7767 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep12633_CR33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature06306","volume":"450","author":"LW Collison","year":"2007","unstructured":"Collison, L. W. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566\u2013569 (2007).","journal-title":"Nature"},{"key":"BFsrep12633_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni.1952","volume":"11","author":"LW Collison","year":"2010","unstructured":"Collison, L. W. et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11, 1093\u20131101 (2010).","journal-title":"Nat Immunol"},{"key":"BFsrep12633_CR35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.immuni.2013.10.016","volume":"39","author":"SL Bailey-Bucktrout","year":"2013","unstructured":"Bailey-Bucktrout, S. L. et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39, 949\u2013962 (2013).","journal-title":"Immunity"},{"key":"BFsrep12633_CR36","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1126\/science.1191996","volume":"329","author":"YP Rubtsov","year":"2010","unstructured":"Rubtsov, Y. P. et al. Stability of the regulatory T cell lineage in vivo. Science 329, 1667\u20131671 (2010).","journal-title":"Science"},{"key":"BFsrep12633_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.immuni.2013.01.013","volume":"38","author":"MD Sharma","year":"2013","unstructured":"Sharma, M. D. et al. An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38, 998\u20131012 (2013).","journal-title":"Immunity"},{"key":"BFsrep12633_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","volume":"321","author":"A Berger","year":"2000","unstructured":"Berger, A. Th1 and Th2 responses: what are they? BMJ 321, 424 (2000).","journal-title":"BMJ"},{"key":"BFsrep12633_CR39","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/eji.200737810","volume":"37","author":"W Niedbala","year":"2007","unstructured":"Niedbala, W. et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37, 3021\u20133029 (2007).","journal-title":"Eur J Immunol"},{"key":"BFsrep12633_CR40","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.4049\/jimmunol.0902739","volume":"184","author":"I Kochetkova","year":"2010","unstructured":"Kochetkova, I., Golden, S., Holderness, K., Callis, G. & Pascual, D. W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184, 7144\u20137153 (2010).","journal-title":"J Immunol"},{"key":"BFsrep12633_CR41","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2337\/db11-0784","volume":"61","author":"M Bettini","year":"2012","unstructured":"Bettini, M., Castellaw, A. H., Lennon, G. P., Burton, A. R. & Vignali, D. A. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 61, 1519\u20131526 (2012).","journal-title":"Diabetes"},{"key":"BFsrep12633_CR42","unstructured":"Leiter, E. H. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Prot Immunol Chapter 15, Unit 15 19 (2001)."},{"key":"BFsrep12633_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature12979","volume":"507","author":"P Shen","year":"2014","unstructured":"Shen, P. et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366\u2013370 (2014).","journal-title":"Nature"},{"key":"BFsrep12633_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","volume":"20","author":"RX Wang","year":"2014","unstructured":"Wang, R. X. et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20, 633\u2013641 (2014).","journal-title":"Nat Med"},{"key":"BFsrep12633_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1515\/JPEM.2003.16.2.203","volume":"16","author":"G Ozer","year":"2003","unstructured":"Ozer, G. et al. Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. JPEM 16, 203\u2013210 (2003).","journal-title":"JPEM"},{"key":"BFsrep12633_CR46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/pedi.12046","volume":"14","author":"J Lempainen","year":"2013","unstructured":"Lempainen, J., Harkonen, T., Laine, A., Knip, M. & Ilonen, J., Finnish, Associations of polymorphisms in non-HLA loci with autoantibodies at the diagnosis of type 1 diabetes: INS and IKZF4 associate with insulin autoantibodies. Ped Diab 14, 490\u2013496 (2013).","journal-title":"Ped Diab"},{"key":"BFsrep12633_CR47","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.diabres.2009.12.016","volume":"87","author":"NM Hasan","year":"2010","unstructured":"Hasan, N. M. et al. Genetic association of the neuropilin-1 gene with type 1 diabetes in children: Neuropilin-1 expression in pancreatic islets. Diab Res Cli Prac 87, e29\u201332 (2010).","journal-title":"Diab Res Cli Prac"},{"key":"BFsrep12633_CR48","first-page":"1649","volume":"41","author":"S Ishida","year":"2000","unstructured":"Ishida, S. et al. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Inv Ophth Vis Sci 41, 1649\u20131656 (2000).","journal-title":"Inv Ophth Vis Sci"},{"key":"BFsrep12633_CR49","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000227762","volume":"30","author":"T Bondeva","year":"2009","unstructured":"Bondeva, T. & Wolf, G. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity. Ameri J Neph 30, 336\u2013345 (2009).","journal-title":"Ameri J Neph"},{"key":"BFsrep12633_CR50","doi-asserted-by":"crossref","unstructured":"Cai, Z. et al. Remission of systemic lupus erythematosus disease activity with regulatory cytokine IL-35 in MRL\/lpr mice. Clin Exp Immunol, 10.1002\/cei.12639 (2015).","DOI":"10.1111\/cei.12639"},{"key":"BFsrep12633_CR51","doi-asserted-by":"crossref","unstructured":"Nakano, S. et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology, 10.1093\/rheumatology\/keu528 (2015).","DOI":"10.1093\/rheumatology\/keu528"},{"key":"BFsrep12633_CR52","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cyto.2015.02.003","volume":"73","author":"Y Zhou","year":"2015","unstructured":"Zhou, Y., Zhang, H. & Li, Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load. Cytokine 73, 169\u2013175 (2015).","journal-title":"Cytokine"},{"key":"BFsrep12633_CR53","first-page":"1206","volume":"16","author":"LF Ding","year":"2014","unstructured":"Ding, L. F. et al. Effects of sublingual immunotherapy on serum IL-17 and IL-35 levels in children with allergic rhinitis or asthma. Zhongguo Dang Dai Er Ke Za Zhi 16, 1206\u20131210 (2014).","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"BFsrep12633_CR54","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/leu.2014.310","volume":"29","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia 29, 939\u2013946 (2015).","journal-title":"Leukemia"},{"key":"BFsrep12633_CR55","first-page":"211","volume":"32","author":"C Chen","year":"2014","unstructured":"Chen, C. et al. Decreased concentration of IL-35 in plasma of patients with asthma and COPD. Asian Pac J Aller Immunol 32, 211\u2013217 (2014).","journal-title":"Asian Pac J Aller Immunol"},{"key":"BFsrep12633_CR56","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.humimm.2014.06.019","volume":"75","author":"Y Yang","year":"2014","unstructured":"Yang, Y. et al. Decreased IL-35 levels in patients with immune thrombocytopenia. Hum Immunol 75, 909\u2013913 (2014).","journal-title":"Hum Immunol"},{"key":"BFsrep12633_CR57","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1210\/endo-103-4-1518","volume":"103","author":"AA Rossini","year":"1978","unstructured":"Rossini, A. A., Williams, R. M., Appel, M. C. & Like, A. A. Sex differences in the multiple-dose streptozotocin model of diabetes. Endocrinology 103, 1518\u20131520 (1978).","journal-title":"Endocrinology"},{"key":"BFsrep12633_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2013.04.020","volume":"63","author":"T Rydgren","year":"2013","unstructured":"Rydgren, T., Oster, E., Sandberg, M. & Sandler, S. Administration of IL-1 trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice. Cytokine 63, 123\u2013129 (2013).","journal-title":"Cytokine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep12633","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:19:49Z","timestamp":1672957189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep12633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,10,16]]}},"alternative-id":["BFsrep12633"],"URL":"https:\/\/doi.org\/10.1038\/srep12633","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]},"assertion":[{"value":"8 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12633"}}